{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:15:27Z","timestamp":1787318127383,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-muscle invasive bladder cancers (NMIBC) pTa-pT1 are depicted by a high risk of recurrence and\/or progression with an unpredictable clinical evolution. Our aim was to identify, from the original resection specimen, tumors that will progress to better manage patients. We previously showed that A-FABP (Adipocyte- Fatty Acid Binding Protein) loss predicted NMIBC progression. Here we determined by immunohistochemistry the prognostic value of E-FABP (Epidermal-Fatty Acid Binding Protein) expression in 210 tumors (80 pTa, 75 pT1, 55 pT2-T4). Thus, E-FABP low expression was correlated with a high grade\/stage, the presence of metastatic lymph nodes, and visceral metastases (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Unlike A-FABP in NMIBC, E-FABP low expression was not associated with RFS or PFS in Kaplan\u2013Meier analysis. But patients of the overall cohort with a high E-FABP expression had a longer mOS (53.8\u00a0months vs. 29.3\u00a0months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.029). The immunohistochemical analysis on the same NMIBC tissue sections revealed that when A-FABP is absent, a high E-FABP expression is detected. E-FABP could compensate A-FABP loss. Interestingly, patients, whose original tumor presents both low E-FABP and negative A-FABP, had the worse survival, those maintaining the expression of both markers had better survival. To conclude, the combined evaluation of A- and E-FABP expression allowed to stratify patients with urothelial carcinoma for optimizing treatment and follow-up.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-65972-8","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:02:28Z","timestamp":1720076548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients"],"prefix":"10.1038","volume":"14","author":[{"given":"In\u00e8s","family":"Saizonou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lascombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Monnien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bedgedjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Kleinclauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paule","family":"Algros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Fauconnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"65972_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"65972_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1365-2559.2008.03025.x","volume":"53","author":"R Montironi","year":"2008","unstructured":"Montironi, R., Lopez-Beltran, A., Scarpelli, M., Mazzucchelli, R. & Cheng, L. Morphological classification and definition of benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. Histopathology 53, 621\u2013633 (2008).","journal-title":"Histopathology"},{"key":"65972_CR3","first-page":"204","volume-title":"TNM Classification of Malignant Tumors","author":"MK Gospodarowicz","year":"2017","unstructured":"Gospodarowicz, M. K. & Mason, M. Urological Tumors. In TNM Classification of Malignant Tumors 8th edn (eds Brierley, D. J. et al.) 204\u2013207 (Wiley, 2017).","edition":"8"},{"key":"65972_CR4","first-page":"1","volume":"37","author":"KH Kurth","year":"2000","unstructured":"Kurth, K. H. et al. Treatment of superficial bladder tumors: Achievements and needs. The EORTC Genitourinary Group. Eur Urol. 37, 1\u20139 (2000).","journal-title":"The EORTC Genitourinary Group. Eur Urol."},{"key":"65972_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","volume":"374","author":"DS Kaufman","year":"2009","unstructured":"Kaufman, D. S., Shipley, W. U. & Feldman, A. S. Bladder cancer. Lancet 374, 239\u2013249 (2009).","journal-title":"Lancet"},{"key":"65972_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1158\/1535-7163.MCT-11-0756","volume":"11","author":"S Richter","year":"2012","unstructured":"Richter, S. & Sridhar, S. S. New directions for biologic targets in urothelial carcinoma. Mol. Cancer Therapeutics. 11, 226\u20131235 (2012).","journal-title":"Mol. Cancer Therapeutics."},{"key":"65972_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"BP Schrier","year":"2004","unstructured":"Schrier, B. P., Hollander, M. P., van Rhijn, B. W., Kiemeney, L. A. & Witjes, J. A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur. Urol. 45, 292\u2013296 (2004).","journal-title":"Eur. Urol."},{"key":"65972_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/bju.13760","volume":"119","author":"SL Woldu","year":"2017","unstructured":"Woldu, S. L., Bagrodia, A. & Lotan, Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 119, 371\u2013380 (2017).","journal-title":"BJU Int."},{"key":"65972_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J. Clin. Oncol. 19, 666\u2013675 (2001).","journal-title":"J. Clin. Oncol."},{"key":"65972_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-018-5137-4","volume":"18","author":"C Mathis","year":"2018","unstructured":"Mathis, C. et al. Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: Investigation with a long-term clinical follow-up. BMC Cancer 18, 1239\u20131252 (2018).","journal-title":"BMC Cancer"},{"key":"65972_CR11","doi-asserted-by":"publisher","first-page":"109336","DOI":"10.1016\/j.cellsig.2019.06.001","volume":"62","author":"IH McKillop","year":"2019","unstructured":"McKillop, I. H., Girardi, C. A. & Thompson, K. J. Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal 62, 109336\u2013109347 (2019).","journal-title":"Cell Signal"},{"key":"65972_CR12","first-page":"4111","volume":"57","author":"M Ostergaard","year":"1997","unstructured":"Ostergaard, M. et al. Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res. 57, 4111\u20134117 (1997).","journal-title":"Cancer Res."},{"key":"65972_CR13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.274.5291.1377","volume":"274","author":"GS Hotamisligil","year":"1996","unstructured":"Hotamisligil, G. S. et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 274, 1377\u20131379 (1996).","journal-title":"Science."},{"key":"65972_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.plipres.2004.05.001","volume":"43","author":"NH Haunerland","year":"2004","unstructured":"Haunerland, N. H. & Spener, F. Fatty acid-binding proteins \u2013 insights from genetic manipulations. Prog. Lipid. Res. 43, 328\u2013349 (2004).","journal-title":"Prog. Lipid. Res."},{"key":"65972_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk, M. et al. Reply to Harry Herr\u2019s Letter to the Editor re: Marko Babjuk, Andreas B\u00f6hle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. Eur. Urol. 71, 447\u201361 (2017).","journal-title":"Eur. Urol."},{"key":"65972_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49, 466\u2013477 (2006).","journal-title":"Eur Urol."},{"key":"65972_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BW van Rhijn","year":"2009","unstructured":"van Rhijn, B. W. et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur. Urol. 56, 430\u2013442 (2009).","journal-title":"Eur. Urol."},{"key":"65972_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/tau.2018.11.05","volume":"8","author":"M Rink","year":"2019","unstructured":"Rink, M., Schwarzenbach, H., Vetterlein, M. W., Riethdorf, S. & Soave, A. The current role of circulating biomarkers in non-muscle invasive bladder cancer. Transl. Androl. Urol. 8, 61\u201375 (2019).","journal-title":"Transl. Androl. Urol."},{"key":"65972_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.21037\/tau.2019.01.15","volume":"8","author":"S Zamboni","year":"2019","unstructured":"Zamboni, S. et al. Prediction tools in non-muscle invasive bladder cancer. Transl. Androl. Urol. 8, 39\u201345 (2019).","journal-title":"Transl. Androl. Urol."},{"key":"65972_CR20","first-page":"4782","volume":"56","author":"JE Celis","year":"1996","unstructured":"Celis, J. E. et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res. 56, 4782\u20134790 (1996).","journal-title":"Cancer Res."},{"key":"65972_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/147323001103900222","volume":"39","author":"R Chen","year":"2011","unstructured":"Chen, R., Feng, C. & Xu, Y. Cyclin-dependent Kinase-associated Protein Cks2 is associated with bladder cancer progression. J. Int. Med. Res. 39, 533\u2013540 (2011).","journal-title":"J. Int. Med. Res."},{"key":"65972_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/(SICI)1522-2683(19990201)20:2<355::AID-ELPS355>3.0.CO;2-N","volume":"20","author":"A Celis","year":"1999","unstructured":"Celis, A. et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 20, 355\u2013361 (1999).","journal-title":"Electrophoresis"},{"key":"65972_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1074\/mcp.M100031-MCP200","volume":"1","author":"JE Celis","year":"2002","unstructured":"Celis, J. E. et al. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol. Cell Proteomics. 1, 269\u2013279 (2002).","journal-title":"Mol. Cell Proteomics."},{"key":"65972_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/pmic.200402015","volume":"6","author":"KH Sheng","year":"2006","unstructured":"Sheng, K. H., Yao, Y. C., Chuang, S. S., Wu, H. & Wu, T. F. Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis. Proteomics 6, 1058\u20131065 (2006).","journal-title":"Proteomics"},{"key":"65972_CR25","doi-asserted-by":"crossref","unstructured":"Guaita-Esteruelas, S., Gum\u00e0, J., Masana, L. & Borr\u00e0s, J. The peritumoural adipose tissue microenvironment and cancer. The roles of fatty acid binding protein 4 and fatty acid binding protein 5. Mol Cell Endocrinol. 462, 107\u2013118 (2018).","DOI":"10.1016\/j.mce.2017.02.002"},{"key":"65972_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1471-2407-12-223","volume":"12","author":"M Kowalewska","year":"2012","unstructured":"Kowalewska, M. et al. Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes. BMC Cancer 12, 223\u2013234 (2012).","journal-title":"BMC Cancer"},{"key":"65972_CR27","doi-asserted-by":"publisher","first-page":"14873","DOI":"10.1007\/s13277-016-5350-1","volume":"37","author":"W Wei","year":"2016","unstructured":"Wei, W. et al. FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer. Tumour Biol. 37, 14873\u201314883 (2016).","journal-title":"Tumour Biol."},{"key":"65972_CR28","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.2147\/CMAR.S181555","volume":"10","author":"JB Lu","year":"2018","unstructured":"Lu, J. B., Cai, S. H., Pan, Y. H. & Yun, J. P. Altered epidermal fatty acid-binding protein expression in hepatocellular carcinoma predicts unfavorable outcomes. Cancer Manag. Res. 10, 6275\u20136284 (2018).","journal-title":"Cancer Manag. Res."},{"key":"65972_CR29","doi-asserted-by":"publisher","first-page":"172637","DOI":"10.1016\/j.ejphar.2019.172637","volume":"862","author":"G Wu","year":"2019","unstructured":"Wu, G. et al. FABP5 is correlated with poor prognosis and promotes tumour cell growth and metastasis in clear cell renal cell carcinoma. Eur. J. Pharmacol. 862, 172637\u2013172649 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"65972_CR30","first-page":"1771","volume":"19","author":"Y Xu","year":"2020","unstructured":"Xu, Y., Xu, W. H., Yang, X. L., Zhang, H. L. & Zhang, X. F. Fatty acid-binding protein 5 predicts poor prognosis in patients with uveal melanoma. Oncol. Lett. 19, 1771\u20131780 (2020).","journal-title":"Oncol. Lett."},{"key":"65972_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1046\/j.1365-201X.2003.01166.x","volume":"178","author":"JF Glatz","year":"2003","unstructured":"Glatz, J. F. et al. Cytoplasmic fatty acid-binding protein facilitates fatty acid utilization by skeletal muscle. Acta Physiol. Scand. 178, 367\u2013371 (2003).","journal-title":"Acta Physiol. Scand."},{"key":"65972_CR32","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/0008-5472.CAN-13-0384","volume":"73","author":"L Levi","year":"2013","unstructured":"Levi, L. et al. Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res. 73, 4770\u20134780 (2013).","journal-title":"Cancer Res."},{"key":"65972_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1442-2050.2007.00759.x","volume":"21","author":"R Ogawa","year":"2008","unstructured":"Ogawa, R. et al. Identification of candidate genes involved in the radiosensitivity of esophageal cancer cells by microarray analysis. Dis. Esophagus. 21, 288\u2013297 (2008).","journal-title":"Dis. Esophagus."},{"key":"65972_CR34","first-page":"4357","volume":"61","author":"C Jing","year":"2001","unstructured":"Jing, C. et al. Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. Cancer Res. 61, 4357\u20134364 (2001).","journal-title":"Cancer Res."},{"key":"65972_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1600-0714.2009.00836.x","volume":"39","author":"LY Fang","year":"2010","unstructured":"Fang, L. Y., Wong, T. Y., Chiang, W. F. & Chen, Y. L. Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J. Oral. Pathol. Med. 39, 342\u2013348 (2010).","journal-title":"J. Oral. Pathol. Med."},{"key":"65972_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/cam4.1020","volume":"6","author":"T Ohata","year":"2017","unstructured":"Ohata, T. et al. Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition. Cancer Med. 6, 1049\u20131061 (2017).","journal-title":"Cancer Med."},{"key":"65972_CR37","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/sj.onc.1206341","volume":"22","author":"J Adamson","year":"2003","unstructured":"Adamson, J. et al. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene 22, 2739\u20132749 (2003).","journal-title":"Oncogene"},{"key":"65972_CR38","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.3892\/ol.2017.6748","volume":"14","author":"G Zhao","year":"2017","unstructured":"Zhao, G., Wu, M., Wang, X., Du, Z. & Zhang, G. Effect of FABP5 gene silencing on the proliferation, apoptosis and invasion of human gastric SGC-7901 cancer cells. Oncol. Lett. 14, 4772\u20134778 (2017).","journal-title":"Oncol. Lett."},{"key":"65972_CR39","first-page":"133","volume":"5","author":"R Hammamieh","year":"2005","unstructured":"Hammamieh, R., Chakraborty, N., Barmada, M., Das, R. & Jett, M. Expression patterns of fatty acid binding proteins in breast cancer cells. J. Exp. Ther. Oncol. 5, 133\u2013143 (2005).","journal-title":"J. Exp. Ther. Oncol."},{"key":"65972_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.2910630225","volume":"63","author":"C Moog-Lutz","year":"1995","unstructured":"Moog-Lutz, C. et al. Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22. Int. J. Cancer 63, 297\u2013303 (1995).","journal-title":"Int. J. Cancer"},{"key":"65972_CR41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/00008390-200212000-00013","volume":"12","author":"MC Brouard","year":"2002","unstructured":"Brouard, M. C., Saurat, J. H., Ghanem, G. & Siegenthaler, G. Urinary excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma. Melanoma Res. 12, 627\u2013631 (2002).","journal-title":"Melanoma Res."},{"key":"65972_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.oraloncology.2005.12.024","volume":"43","author":"RS Uma","year":"2007","unstructured":"Uma, R. S., Naresh, K. N., D\u2019Cruz, A. K., Mulherkar, R. & Borges, A. M. Metastasis of squamous cell carcinoma of the oral tongue is associated with down-regulation of epidermal fatty acid binding protein (E-FABP). Oral. Oncol. 43, 27\u201332 (2007).","journal-title":"Oral. Oncol."},{"key":"65972_CR43","doi-asserted-by":"publisher","first-page":"234629","DOI":"10.1155\/2010\/234629","volume":"2010","author":"E Morgan","year":"2010","unstructured":"Morgan, E., Kannan-Thulasiraman, P. & Noy, N. Involvement of fatty acid binding protein 5 and PPAR\u03b2\/\u03b4 in prostate cancer cell growth. PPAR Res. 2010, 234629\u2013234638 (2010).","journal-title":"PPAR Res."},{"key":"65972_CR44","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/ijc.24112","volume":"124","author":"G Boiteux","year":"2009","unstructured":"Boiteux, G. et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int. J. Cancer 124, 1820\u20131828 (2009).","journal-title":"Int. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65972-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:03:08Z","timestamp":1720076588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65972-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["65972"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-65972-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15390"}}